There’s a fundamental shift underway in the biotechnology investment world, particularly for highly specialized fields such as pharmaceuticals and genetic research. Investors, it seems, are getting educated.
On a recent earnings call, the CEO of a mid-size pharmaceutical company was fielding all the usual questions about the firm: earnings projections, R&D spending, sales efforts, etc. Then [...]